What we do—

Changing the world

UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.

Read More
Latest news—

UCLB launches funding for early-stage social ventures

UCLB, part of UCL Innovation & Enterprise, launches its search for early-stage social ventures to benefit from Proof of Concept funding.

Read More
Featured Technology—

MAGNETIC MICROBUBBLES

Magnetic microbubbles can be injected into the blood stream and may be directed to a specific body location by the application of an external magnetic field. They enhance ultrasound images, and can be used to deliver, and promote uptake of, cargo molecules such as drugs, antibodies or DNA. They thus have many potential applications in clinical settings, as well as in both basic and medical research.

Read more
Spotlight—

How does Portico Ventures support non-patentable and fast-to-deploy technologies?

The following interview took place in April 2019 towards the end of the one-year pilot phase of Portico Ventures. Following positive feedback from the Department of Computer Science where the pilot ran, Portico Ventures is now rolling out more widely across the university. Visit our newsroom to find out more.

Read More
Featured Technology—

SnakeGrid

SnakeGrid is a way of developing low-distortion coordinate systems for large engineering projects.

Read more

Latest news and highlights

Read More News

UCLB launches funding for early-stage social ventures

/ Social Ventures, UCLB News
UCLB, part of UCL Innovation & Enterprise, launches its search for early-stage social ventures to benefit from Proof of Concept ...

Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO1 for Treatment of Acute Lymphoblastic Leukemia

/ Spinout News
LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment ...

New commercialisation models to help bring more UCL discoveries to market

/ UCLB News
The launch of Portico Ventures sees the introduction of two new models for intellectual property (IP) commercialisation to support UCL ...

UCLB reaches an exclusive license agreement for the treatment of Alpha-1-Antitrypsin Deficiency

/ UCLB News
UCLB has concluded an exclusive agreement to license a collection of pre-clinical small molecule compounds for the treatment of alpha-1-antitrypsin ...

FIND THE RIGHT MATCH

Whether you’re an academic or looking for technologies, find your UCLB contact here.

 

Commercialising technology since 1993

0
Active spinouts
0
Active licences in 2018
0
Drug discoveries
0
New patent applications